LYEL logo

LYEL
Lyell Immunopharma Inc

434
Mkt Cap
$403.68M
Volume
22,459.00
52W High
$45.00
52W Low
$7.65
PE Ratio
-1.36
LYEL Fundamentals
Price
$17.24
Prev Close
$17.30
Open
$16.96
50D MA
$20.97
Beta
1.62
Avg. Volume
87,470.17
EPS (Annual)
-$16.06
P/B
1.47
Rev/Employee
$223.60
$329.90
Loading...
Loading...
News
all
press releases
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL)
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
News Placeholder
More News
News Placeholder
Lyell Immunopharma (LYEL) to Release Quarterly Earnings on Tuesday
Lyell Immunopharma (NASDAQ:LYEL) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-lyell-immunopharma-inc-stock...
News Placeholder
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six ratings firms that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, three have iss...
News Placeholder
Lyell Immunopharma (NASDAQ:LYEL) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen cut shares of Lyell Immunopharma from a "hold" rating to a "sell" rating in a research note on Saturday...
News Placeholder
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap Down - Here's What Happened
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap Down - Here's What Happened...
News Placeholder
Lyell Immunopharma (NASDAQ:LYEL) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen upgraded Lyell Immunopharma from a "sell" rating to a "hold" rating in a research note on Saturday...
News Placeholder
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Large Increase in Short Interest
Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totaling 1,138,296 shares, a...
News Placeholder
Lyell Immunopharma (NASDAQ:LYEL) Shares Down 4% - Should You Sell?
Lyell Immunopharma (NASDAQ:LYEL) Trading Down 4% - Time to Sell...
News Placeholder
Lyell Immunopharma (NASDAQ:LYEL) Stock Price Up 6.9% - Should You Buy?
Lyell Immunopharma (NASDAQ:LYEL) Trading Up 6.9% - Still a Buy...
News Placeholder
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Consensus Recommendation of "Hold" from Analysts
Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating and three have assigned a b...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available